OVIOPEPTIDES

Exclusive Offer

Free Bacteriostatic Water

Sign up and get a free bacteriostatic water added to your next order, automatically.

Research Use OnlyGet free bacteriostatic water added to your next order when you join the list.

Semaglutide — Canada Research Brief

By Dr. Elena Morozova, PhDReviewed by Dr. Elena Morozova, PhDPublished April 11, 2026Last reviewed April 11, 20262 min read
Quick answer

Semaglutide is a long-acting GLP-1 receptor agonist approved by Health Canada for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy).

Key facts

Canonical nameSemaglutide
Alternate namesOzempic, Wegovy, Rybelsus, NN9535
Drug classGLP-1 receptor agonist
CAS number910463-68-2
Molecular formulaC187H291N45O59
Molecular weight4113.58 g/mol
COA pending

Mechanism

Semaglutide activates the GLP-1 receptor, a class B G-protein-coupled receptor expressed in pancreatic β-cells, gastric smooth muscle, and hypothalamic appetite circuits. Downstream effects include:

  • Glucose-dependent insulin secretion from pancreatic β-cells, which improves postprandial glycaemia without the hypoglycaemia risk of sulfonylureas.
  • Glucagon suppression from α-cells.
  • Delayed gastric emptying, which flattens postprandial glucose peaks and contributes to early satiety.
  • Central appetite suppression via GLP-1 receptor populations in the arcuate nucleus and area postrema.

The fatty-acid side chain on Lys26 binds reversibly to plasma albumin, which protects the peptide from DPP-4 cleavage and renal clearance and gives semaglutide its ~165-hour half-life — the basis for once-weekly dosing.

Clinical evidence

The most-cited dataset for semaglutide in weight management is the STEP programme — eight phase-3 trials published 2021–2023. STEP 1 (Wilding et al., NEJM 2021) reported a mean weight reduction of −14.9% at 68 weeks with once-weekly 2.4 mg subcutaneous dosing versus −2.4% for placebo, in adults with BMI ≥30 or ≥27 with comorbidity.

For cardiovascular safety, SUSTAIN-6 (Marso et al., NEJM 2016) demonstrated a 26% relative risk reduction in the primary MACE composite endpoint in adults with type 2 diabetes at elevated cardiovascular risk.

How Canadian researchers source semaglutide

Canadian labs sourcing research-grade semaglutide should verify three things on every vendor: (1) per-batch HPLC purity ≥98%, (2) mass spectrometry confirming the expected 4,113.58 g/mol mass, and (3) domestic Canadian shipping to avoid customs holds on international incretin peptide shipments.

Comparisons

Storage

Store lyophilised semaglutide at −20°C for long-term storage. Reconstituted peptide is stable refrigerated at 2–8°C for approximately 4 weeks. Avoid repeated freeze-thaw cycles. See our reconstitution guide for step-by-step handling.

Frequently asked questions

What is semaglutide?
Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist approved by Health Canada and the U.S. FDA for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). It is a 31-amino-acid peptide with a fatty-acid side chain that binds albumin, extending its half-life to roughly one week.
Is semaglutide approved in Canada?
Yes, as a prescription drug under the brands Ozempic, Rybelsus, and Wegovy. Research-grade semaglutide sold as a laboratory chemical is a separate, unapproved form that is for non-clinical laboratory research use only — it is not a substitute for a prescribed medication.
How does semaglutide differ from tirzepatide and retatrutide?
Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 / GIP co-agonist. Retatrutide is an investigational triple agonist adding glucagon receptor activity. In head-to-head clinical programmes, mean weight reduction ranks retatrutide > tirzepatide > semaglutide, although only semaglutide and tirzepatide are approved.
What is semaglutide's molecular weight?
Semaglutide has a molecular weight of 4,113.58 g/mol, a molecular formula of C187H291N45O59, and CAS number 910463-68-2. It is manufactured by solid-phase peptide synthesis with a C18 fatty-acid spacer attached to Lys26.

References

  1. [1]Wilding JPH, Batterham RL, Calanna S, et al.. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021. DOI: 10.1056/NEJMoa2032183
  2. [2]Marso SP, Bain SC, Consoli A, et al.. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine, 2016. DOI: 10.1056/NEJMoa1607141
  3. [3]National Center for Biotechnology Information. PubChem CID 56843331 — Semaglutide, 2024

Related research